Streetbeat News

Revenues

APO

Apollo Global Management (NYSE: APO) reported Q2 2024 earnings per share (EPS) of $1.64, missing the analyst estimate of $1.76. However, the company reported sales of $6.018 billion, significantly beating the estimate of $3.877 billion.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:41 am

MBLY

Mobileye Global has updated its financial guidance for the 2024 fiscal year, lowering its revenue expectations to $1.60B-$1.68B from the previous $1.83B-$1.96B. The company also adjusted its operating loss and adjusted operating income projections.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:39 am

MRNA

Moderna has revised its 2024 expected net product sales from its respiratory franchise to $3B-$3.5B, down from prior guidance of $4B. The revision is due to low EU sales, potential revenue deferrals, and increased competition in the U.S. Cost of sales is expected to be 40-50% of product sales, with R&D expenses at $4.5B, SG&A expenses at $1.3B, and capital expenditures at $0.9B. Year-end cash and investments are projected to be $9B.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:39 am

MRNA

Moderna shares are trading lower after the company revised its 2024 expectations due to low EU sales, potential revenue deferrals for certain international sales into 2025, and an increasingly competitive environment for respiratory vaccines in the US.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:38 am

BAND

Bandwidth has reiterated its FY24 revenue guidance of $710M-$720M, which is in line with the $715.94M estimate. The company also provided guidance for Q3 2024 with expected revenue of $180M-$184M and adjusted EBITDA of $18M-$20M.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:37 am

BAND

Bandwidth Inc. (BAND) has provided its financial outlook for Q3 2024, expecting revenue between $180M and $184M, surpassing the estimated $178.65M. The company also provided full-year 2024 guidance with revenue projected between $710M and $720M and adjusted EBITDA between $72M and $76M.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:36 am

AGIO

Agios Pharmaceuticals (NASDAQ:AGIO) reported Q2 2024 GAAP EPS of $(1.69), missing the $(1.60) estimate. Sales were $8.615M, missing the $9.307M estimate but up 28.35% YoY.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:35 am

TRP

TC Energy (NYSE:TRP) reported Q2 2024 adjusted EPS of C$0.94, beating the C$0.91 estimate. Sales were C$4.085 billion, surpassing the C$3.804 billion estimate. Despite a slight year-over-year EPS decline, sales increased by 6.66%.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:35 am

ITT

ITT maintains its FY24 revenue, margin, EPS, and free cash flow guidance despite the Wolverine divestiture. The company expects revenue growth of 9% to 12%, operating margin of 16.9% to 17.5%, and adjusted EPS of $5.65 to $5.90. Free cash flow is projected to be $435 million to $475 million.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:35 am

MRNA

Moderna reported its Q2 2024 financial results, with a GAAP EPS of $(3.33), beating the estimate of $(3.36). Sales were $241 million, surpassing the expected $132.183 million.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:34 am